10 Best Small-Cap Stocks to Buy Now

7. Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Analyst Upside: 54.79%

No. of Hedge Fund Holders: 33

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) is a biopharmaceutical company that is engaged in the study and development of treatments related to cellular metabolism and blood-related diseases, with several therapies still in early-stage development.

On February 15, Scotiabank analyst Greg Harrison slightly lowered the price target on AGIO shares from $75 to $74 while keeping an Outperform rating on the shares. Harrison is optimistic about the company’s regulatory and clinical execution in Q4 2024. During the quarter, the company delivered remarkable results with a net Pyrukynd revenue of $10.7 million, up by nearly 51% from a year ago. Scotiabank is optimistic about the company’s progress and believes Agios is well-equipped to accelerate the growth of the Pyrukynd franchise. In addition to that, the analyst remains cautiously optimistic about Mitapivat’s point of sickening. The company has posted positive top-line results from the Phase 3 trial of Mitapivat for pediatric patients with PK deficiency.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) is preparing for two additional commercial launches. Pyrukynd’s potential approval and launch in thalassemia are expected in September 2025 and in sickle cell disease in 2026. The company completed the enrollment in the phase 3 rise-up study for sickle cell disease. Agios has a strong balance sheet with nearly $1.5 billion in cash and cash equivalents.